Hepatitis C virus: Up to the minute

Liver Transplantation

Volumn 16, Issue SUPPL. 2, 2010, Pages

  Roche, Bruno ^a,b,c   Samuel, Didier ^a,b,c  

^a HÔPITAL PAUL BROUSSE   (France)

^b INSERM   (France)

^c Universite Paris Sud   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; INTERFERON; PEGINTERFERON; PEGINTERFERON ALPHA2A; RIBAVIRIN;

ANEMIA; ANTIVIRAL THERAPY; ARTICLE; BACTERIAL INFECTION; CYTOMEGALOVIRUS; DECOMPENSATED LIVER CIRRHOSIS; GRAFT SURVIVAL; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; INFECTION; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER TRANSPLANTATION; MIXED INFECTION; NEUTROPENIA; PRIORITY JOURNAL; RISK FACTOR; THROMBOCYTOPENIA; VIRUS LOAD;

EID: 78651407864     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.22154     Document Type: Article

References (29)

1. Forman LM, Lewis JD, Berlin JA, Feldman HI, Lucey MR., The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002; 122: 889-896. (Pubitemid 34267271)
2. Roche B, Samuel D., Risk factors for hepatitis C recurrence after liver transplantation. J Viral Hepat 2007; 14 (suppl 1): 89-96. (Pubitemid 47624117)
3. Berenguer M, Prieto M, Rayon JM, Mora J, Pastor M, Ortiz V, et al. Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation. Hepatology 2000; 32 (pt 1): 852-858.
4. Forns X, Garcia-, Retortillo M, Serrano T, Feliu A, Suarez F, de la Mata M, et al. Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation. J Hepatol 2003; 39: 389-396. (Pubitemid 37070256)
5. Everson GT, Trotter J, Forman L, Kugelmas M, Halprin A, Fey B, et al. Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy. Hepatology 2005; 42: 255-262. (Pubitemid 41061075)
6. Chalasani N, Manzarbeitia C, Ferenci P, Vogel W, Fontana RJ, Voigt M, et al. Peginterferon alfa-2a for hepatitis C after liver transplantation: two randomized, controlled trials. Hepatology 2005; 41: 289-298. (Pubitemid 40165372)
7. Carrion JA, Martinez-Bauer E, Crespo G, Ramirez S, Perez-del-Pulgar S, Garcia-, Valdecasas JC, et al. Antiviral therapy increases the risk of bacterial infections in HCV-infected cirrhotic patients awaiting liver transplantation: a retrospective study. J Hepatol 2009; 50: 719-728.
8. Samuel D, Bizollon T, Feray C, Roche B, Ahmed SN, Lemonnier C, et al. Interferon-alpha 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: a randomized study. Gastroenterology 2003; 124: 642-650. (Pubitemid 36268483)
9. Carrion JA, Navasa M, Garcia-Retortillo M, Garcia-Pagan JC, Crespo G, Bruguera M, et al. Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: a randomized controlled study. Gastroenterology 2007; 132: 1746-1756. (Pubitemid 46695723)
10. Berenguer M., Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin. J Hepatol 2008; 49: 274-287.
11. Wang CS, Ko HH, Yoshida EM, Marra CA, Richardson K., Interferon-based combination anti-viral therapy for hepatitis C virus after liver transplantation: a review and quantitative analysis. Am J Transplant 2006; 6: 1586-1599. (Pubitemid 43945798)
12. Xirouchakis E, Triantos C, Manousou P, Sigalas A, Calvaruso V, Corbani A, et al. Pegylated-interferon and ribavirin in liver transplant candidates and recipients with HCV cirrhosis: systematic review and meta-analysis of prospective controlled studies. J Viral Hepat 2008; 15: 699-709.
13. Garcia-Retortillo M, Forns X, Feliu A, Moitinho E, Costa J, Navasa M, et al. Hepatitis C virus kinetics during and immediately after liver transplantation. Hepatology 2002; 35: 680-687. (Pubitemid 34183974)
14. Shackel NA, Jamias J, Rahman W, Prakoso E, Strasser SI, Koorey DJ, et al. Early high peak hepatitis C viral load levels independently predict hepatitis C-related liver failure post-liver transplantation. Liver Transpl 2009; 15: 709-718.
15. McCaughan GW, Zekry A., Mechanisms of HCV reinfection and allograft damage after liver transplantation. J Hepatol 2004; 40: 368-374. (Pubitemid 38230834)
16. Carrion JA, Fernandez-Varo G, Bruguera M, Garcia-Pagan JC, Garcia-Valdecasas JC, Perez-Del-Pulgar S, et al. Serum fibrosis markers identify patients with mild and progressive hepatitis C recurrence after liver transplantation. Gastroenterology 2010; 138: 147-158.
17. Carrion JA, Torres F, Crespo G, Miquel R, Garcia-Valdecasas JC, Navasa M, et al. Liver stiffness identifies two different patterns of fibrosis progression in patients with hepatitis C virus recurrence after liver transplantation. Hepatology 2010; 51: 23-34.
18. Blasco A, Forns X, Carrion JA, Garcia-Pagan JC, Gilabert R, Rimola A, et al. Hepatic venous pressure gradient identifies patients at risk of severe hepatitis C recurrence after liver transplantation. Hepatology 2006; 43: 492-499.
19. Eurich D, Boas-Knoop S, Ruehl M, Schulz M, Carillo ED, Bahra M, et al. IL-28b gene polymorphism influences histological and biochemical severity of graft hepatitis after liver transplantation for HCV-induced liver disease. Liver Transpl 2010; 16: S119.
20. Berenguer M, Royuela A, Zamora J., Immunosuppression with calcineurin inhibitors with respect to the outcome of HCV recurrence after liver transplantation: results of a meta-analysis. Liver Transpl 2007; 13: 21-29. (Pubitemid 46099970)
21. Roche B, Sebagh M, Canfora ML, Antonini T, Roque-Afonso AM, Delvart V, et al. Hepatitis C virus therapy in liver transplant recipients: response predictors, effect on fibrosis progression, and importance of the initial stage of fibrosis. Liver Transpl 2008; 14: 1766-1777.
22. Crippin JS, McCashland T, Terrault N, Sheiner P, Charlton MR., A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation. Liver Transpl 2002; 8: 350-355. (Pubitemid 34467369)
23. Thomas RM, Brems JJ, Guzman-Hartman G, Yong S, Cavaliere P, Van Thiel DH., Infection with chronic hepatitis C virus and liver transplantation: a role for interferon therapy before transplantation. Liver Transpl 2003; 9: 905-915. (Pubitemid 37098838)
24. Mazzaferro V, Tagger A, Schiavo M, Regalia E, Pulvirenti A, Ribero ML, et al. Prevention of recurrent hepatitis C after liver transplantation with early interferon and ribavirin treatment. Transplant Proc 2001; 33: 1355-1357. (Pubitemid 32237879)
25. Shergill AK, Khalili M, Straley S, Bollinger K, Roberts JP, Ascher NA, et al. Applicability, tolerability and efficacy of preemptive antiviral therapy in hepatitis C-infected patients undergoing liver transplantation. Am J Transplant 2005; 5: 118-124. (Pubitemid 40095135)
26. Sugawara Y, Makuuchi M, Matsui Y, Kishi Y, Akamatsu N, Kaneko J, et al. Preemptive therapy for hepatitis C virus after living-donor liver transplantation. Transplantation 2004; 78: 1308-1311. (Pubitemid 39507969)
27. Navasa M, Casanovas T, Berenguer M, Fernandez I, Salcedo M, Castells L, et al. Higher sustained virologic response and histologic improvement in recurrent hepatitis C after pegylated interferon plus ribavirin therapy under cyclosporine-based versus tacrolimus-based immunosuppressive therapy [abstract]. J Hepatol 2010; 52 (suppl 1): 24.
28. Berenguer M, Aguilera V, Prieto M, Ortiz C, Rodriguez M, Gentili F, et al. Worse recent efficacy of antiviral therapy in liver transplant recipients with recurrent hepatitis C: impact of donor age and baseline cirrhosis. Liver Transpl 2009; 15: 738-746.
29. Berenguer M, Palau A, Aguilera V, Rayon JM, Juan FS, Prieto M., Clinical benefits of antiviral therapy in patients with recurrent hepatitis C following liver transplantation. Am J Transplant 2008; 8: 679-687. (Pubitemid 351287553)